2,331 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Downtrend
Article Searches
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Hrt Financial Llc Buys iShares Inc MSCI Brazil, VanEck Vectors Gold Miners, iShares China ... http://www.gurufocus.com/news/817539/hrt-financial-llc-buys-ishares-inc-msci-brazil-vaneck-vectors-gold-miners-ishares-china-largecap-sells-spdr-sp-500-amazoncom-inc-marathon-petroleum-corp Feb 15, 2019 - Hrt Financial Llc Buys iShares Inc MSCI Brazil, VanEck Vectors Gold Miners, iShares China Large-Cap, Sells SPDR S&P 500, Amazon.com Inc, Marathon Petroleum Corp, Stocks: EWZ,GDX,FXI,GDXJ,WFC,PFE,AVGO,TVIX,MRK,D,AVT,CI,AM, release date:Feb 15, 2019
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review http://www.zacks.com/stock/news/354979/sareptas-nda-for-dmd-drug-golodirsen-gets-priority-review?cid=CS-ZC-FT-354979 Feb 15, 2019 - FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4 http://www.zacks.com/stock/news/354369/exelixis-exel-earnings-revenues-beat-estimates-in-q4?cid=CS-ZC-FT-354369 Feb 13, 2019 - Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Bristol-Myers' Sprycel Gets European Nod for Label Expansion http://www.zacks.com/stock/news/354050/bristol-myers-sprycel-gets-european-nod-for-label-expansion?cid=CS-ZC-FT-354050 Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review http://www.zacks.com/stock/news/353912/pfizer-sbla-for-kidney-cancer-drug-combo-gets-priority-review?cid=CS-ZC-FT-353912 Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
FDA accepts Pfizer's marketing application for Bavencio + Inlyta for RCC https://seekingalpha.com/news/3432000-fda-accepts-pfizers-marketing-application-bavencio-inlyta-rcc?source=feed_news_all Feb 12, 2019 - Pfizer (NYSE:PFE) and alliance partner Merck KGaA (OTCPK:MKGAY) announce that the FDA has accepted under Priority Review the supplemental marketing application seeking approval for BAVENCIO (avelumab)
Stock Market News For Feb 12, 2019 http://www.zacks.com/stock/news/353887/stock-market-news-for-feb-12-2019?cid=CS-ZC--353887 Feb 12, 2019 - Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.
Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake http://www.zacks.com/stock/news/353577/lilly-to-begin-exchange-offer-for-sale-of-balance-elanco-stake?cid=CS-ZC-FT-353577 Feb 11, 2019 - Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology https://seekingalpha.com/article/4239823-glaxosmithkline-merck-kgaa-position-next-wave-immuno-oncology?source=feed_sector_healthcare Feb 11, 2019 - GSK collaborates with Merck KGaA on M7824, a TGF-beta.M7824 represents a class of agents considered to be the future of Immuno-Oncology.Late stage trials are needed to validate, M7824; if successful,

Pages: 123456...234

Page 1>

Related Companies

Name Exchange Price Mkt Cap
NVS Novartis AG NYSE $85.13 $197.65B
MRK Merck & Company, Inc. NYSE $70.42 $187.28B
ABBV AbbVie Inc. NYSE $95.37 $144.42B
JNJ Johnson & Johnson NYSE $139.96 $375.48B
ABT Abbott Laboratories NYSE $67.67 $118.71B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Pfizer
PFE - Google Finance https://www.google.com/finance?q=PFE Industry related info and international coverage Summary News
PFE - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=PFE Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options